Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

A buy-side analyst with over 15 years of experience investing in Asian markets and specializing in the mid-small cap space, emphasizing value investing in companies with good free cash flows/dividends and long-term holding horizons. 
Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd. It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity, Bottom-up Analyst

UMP Healthcare (722 HK): Parsing the Announcement on The Major One-Time Gain

UMP Healthcare (722 HK) FY24 Results and Concall: 7x FY25PE,1.2x EV-EBITDA and 9% Dividend Yield

UMP Healthcare (722 HK): Deep Value Turnaround in FY25

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

Equity Bottom-Up

<ul>
<li>We met with <a href="https://www.smartkarma.com/entities/ump-healthcare-holdings-ltd" target="_blank" rel="noopener">UMP Healthcare (722 HK)</a> in Hong Kong. We believe management's cost control initiatives are bearing fruit and will see an inflection in earnings in FY25. </li>
<li>The weak consumption sentiment is setting a landscape for asset disposals, such as <a href="https://www.smartkarma.com/entities/ec-healthcare" target="_blank" rel="noopener">EC Healthcare (2138 HK)</a> 's <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1106/2024110601562.pdf" target="_blank" rel="noopener">436 mn HKD</a> disposal of medical imaging to AIA. </li>
<li>We believe the company is a multi-bagger trading at 6.8x PE FY25e. It has ~80% of its market cap in cash (260+ mn HKD) and a ~10% dividend yield. </li>
</ul>


We met with UMP Healthcare (722 HK) in Hong Kong. We believe management's cost control initiatives are bearing fruit and will see an inflection in earnings in FY25. 
The weak consumption sentiment is setting a landscape for asset disposals, such as EC Healthcare (2138 HK) 's 436 mn HKD disposal of medical imaging to AIA. 
We believe the company is a multi-bagger trading at 6.8x PE FY25e. It has ~80% of its market cap in cash (260+ mn HKD) and a ~10% dividend yield. 


UMP Healthcare (722 HK): Postcard From Hong Kong and Webinar Updates